SMC Accepts First Drug to Improve Survival in Uveal Melanoma Edited by Zeel Mehta

https://www.medscape.com/viewarticle/smc-accepts-first-drug-improve-survival-uveal-melanoma-2026a1000npg?src= The Scottish Medicines Consortium (SMC) has accepted tebentafusp (Kimmtrak, Immunocore Ltd) for use within NHS Scotland as monotherapy for adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. The decision follows a second resubmission assessed under the SMC's end-of-life and orphan medicine process and applies only in the context of an approved NHS Scotland Patient Access Scheme underpinning the cost-effectiveness case.